Epertinib
CAS: 908305-13-5
Rif. 3D-ILB30513
1mg | Fuori produzione | ||
5mg | Fuori produzione | ||
10mg | Fuori produzione | ||
25mg | Fuori produzione | ||
50mg | Fuori produzione |
Informazioni sul prodotto
Epertinib is a tyrosine kinase inhibitor that targets epidermal growth factor receptor (EGFR) and HER2. It is used to treat patients with cancer who have specific mutations in the EGFR or HER2 genes. These mutations are found in about 20% of all breast cancers, and may be associated with worse prognosis. Epertinib is active against EGFR-mutated colorectal cancer, lung adenocarcinoma, and some types of brain cancer. It has also been shown to inhibit the growth of solid tumours in mice. In addition, epertinib may be useful for treating metastatic her2-positive breast cancer, as it blocks the growth factor receptor downstream of HER2 signalling (EGFR).